Clinical trials: Mental Depression
Bipolar Disorder
Depression And Bipolar Disorder
This study is an 8-week evaluation of an investigational drug for treating depression in bipolar patients. Depressed patients will be given either an investigational drug or placebo and receive psychiatric assessments of their…
- Trial name
- NCT00274677
- Testing
- lamotrigine
- Where
- 19 sites in United States
- Volunteers
- 221 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of ONO-2333Ms in patients with Recurrent Major Depressive Disorder
- Trial name
- NCT00514865
- Testing
- ONO-2333Ms Experimental 2, ONO-2333Ms Experimental 1
- Where
- United States
- Volunteers
- 278 people
- Sponsor
- Ono Pharma USA Inc
Major Depressive Disorder
Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
To evaluate the long-term safety and tolerability of flexible doses, 15 and 20 mg/day, of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD)
- Trial name
- NCT01323478
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 71 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder, Excessive Sleepiness
Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers
To evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GATE-101 in normal human volunteers
- Trial name
- NCT04618263
- Testing
- GATE-101
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Syndeio Biosciences, Inc
Depressive Disorder, Major
An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms
The purpose of this study is to evaluate the efficacy and safety of long term escitalopram treatment in participants with Major Depressive Disorder (MDD) with associated anxiety symptoms.
- Trial name
- Lexapro (NCT01814098)
- Testing
- Escitalopram
- Where
- 10 sites in China
- Volunteers
- 318 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Major Depressive Disorder
Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder
To compare the antidepressant efficacy and safety of DVS-233 SR with those of placebo in adult outpatients with MDD.
- Trial name
- NCT00090649
- Testing
- DVS-233 SR
- Volunteers
- 369 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder, Major
A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the dose-response relationship of 2 doses of JNJ-42847922 before interim analysis, and potentially 3 doses based on interim analysis results, compared to placebo as adjunctive therapy to an…
- Trial name
- NCT03227224
- Testing
- JNJ-42847922
- Where
- 101 sites in United States, Bulgaria and 6 more
- Volunteers
- 287 people
- Sponsor
- Janssen Research & Development, LLC
Healthy Male
Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart
This is a two part study. Part A will determine the maximum tolerated dose of TC-5214 administered to healthy male subjects in single ascending oral doses.
- Trial name
- NCT01359618
- Testing
- TC-5214, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Major Depressive Disorder (MDD)
A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD)
Study Overview This clinical trial is a Phase 3 research study designed to test the safety and effectiveness of an investigational drug called REL-1017 (esmethadone HCl).
- Trial name
- NCT06735079
- Testing
- REL1017 (esmethadone HCI) (active drug)
- Where
- 2 sites in Italy, Switzerland
- Sponsor
- MGGM LLC
Depressive Disorder, Treatment-Resistant
Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)
This is a pre-approval access program (PAAP) for eligible participants. The main purpose of this program is to provide access to esketamine nasal spray to eligible participant with treatment-resistant depression (TRD), who have…
- Trial name
- NCT03829579
- Testing
- Esketamine
- Sponsor
- Janssen Research & Development, LLC
Depression
Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)
The primary objective is to demonstrate whether the addition of pipamperone 5 mg twice daily (bd) to citalopram, 40 mg daily in patients suffering from MDD will improve the efficacy of citalopram 40 mg in these patients.
- Trial name
- NCT00672659
- Testing
- Citalopram + Pipamperone, Citalopram
- Where
- United Kingdom
- Volunteers
- 165 people
- Sponsor
- PharmaNeuroBoost N.V.
Depression, Pain
Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain
The purposes of this study are to determine whether an investigational drug can help patients suffering from major depression with pain symptoms, and gather data on the safety of the investigational drug including any side…
- Trial name
- NCT00036335
- Testing
- Duloxetine Hydrochloride
- Where
- 25 sites in United States
- Volunteers
- 286 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects
GSK1144814 is a potent, insurmountable antagonist at human neurokinin-1 (NK1) and neurokinin-3 (NK3) receptors with the potential to treat multiple symptom domains of schizophrenia and be an efficacious antidepressant.
- Trial name
- MNK112891 (NCT01090440)
- Testing
- GSK1144814
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Treatment-Resistant
Treatment Resistant Depression in America Latina
The purpose of this study is to estimate the prevalence of Treatment Resistant Depression (TRD) among Major Depressive Disorder (MDD) participants being treated in a psychiatry reference site (example, clinic, ambulatory…
- Trial name
- TRAL (NCT03207282)
- Where
- 33 sites in Argentina, Brazil and 2 more
- Volunteers
- 1,539 people
- Sponsor
- Janssen-Cilag, S.A.
Major Depressive Disorder
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
This is an open-label, parallel-group study to evaluate the safety and efficacy of Ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).
- Trial name
- NCT06126497
- Testing
- Ropanicant
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Suven Life Sciences Limited
Depression, Anxiety, Healthy
Voice Biomarkers Predictive of Depression and Anxiety
The objective of this study is to collect data to improve the sensitivity and specificity of Kintsugi Voice's (formerly KiVATM) predictions on audio files.
- Conditions
- Depression, Anxiety, Healthy, Mental Health Wellness 1
- Trial name
- NCT05455905
- Testing
- Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, Hamilton Depression Rating Scale
- Where
- United States
- Volunteers
- 19,533 people
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Major Depressive Disorder
The Effect of tDCS in Patients With Moderate to Severe Major Depressive Disorder
Study Type: Interventional Study Design: Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)…
- Trial name
- NCT02657980
- Testing
- Yband(YDT-201N)
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- Ybrain Inc.
Major Depressive Disorder
Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder
To evaluate the long-term safety and tolerability of brexpiprazole as adjunctive treatment in patients with Major Depressive Disorder (MDD)
- Trial name
- NCT01944969
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Bipolar Disorder
ADH.E.R.E.: Therapeutic ADHerence and Treatment Strategies: A Mental Health Registry
The purpose of this study is to find out how well new treatment plans are followed by outpatients with major mental illnesses (schizophrenia, bipolar disorder, depression, personality disorder) and to determine the relationship…
- Conditions
- Schizophrenia, Bipolar Disorder, Depression, Personality Disorder
- Trial name
- NCT00264069
- Testing
- antipsychotic, antidepressants
- Volunteers
- 2,622 people
- Sponsor
- Janssen-Cilag, S.A.
Major Depressive Disorder
Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder
The purpose of this study is to determine safety \& efficacy of SEROQUEL SR™ in the treatment of major depressive disorder compared to placebo \& to evaluate quality of sleep, overall quality of life, and effect, if any, on…
- Trial name
- AMETHYST (NCT00278941)
- Testing
- Quetiapine Fumarate Sustained Release
- Where
- 168 sites in United States, Bulgaria and 6 more
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.